
Phase 2 Clinical Trial of AL001 for Major Depressive Disorder: Initiation Date Set for Late 2025
Alzamend announced its plans to initiate a highly anticipated phase 2 clinical study of AL001, a novel lithium-delivery system for the treatment of patients with major depressive disorder (MDD), in late 2025. Alzamend aims to explore the unique properties …